- Home
- TECH vs RLAY Comparison
TECH vs RLAY Comparison
Compare TECH & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TECH
- RLAY
- Stock Information
- Founded
- TECH 1976
- RLAY 2015
- Country
- TECH United States
- RLAY United States
- Employees
- TECH N/A
- RLAY N/A
- Industry
- TECH Biotechnology: Biological Products (No Diagnostic Substances)
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TECH Health Care
- RLAY Health Care
- Exchange
- TECH Nasdaq
- RLAY Nasdaq
- Market Cap
- TECH 7.8B
- RLAY 576.1M
- IPO Year
- TECH 1989
- RLAY 2020
- Fundamental
- Price
- TECH $53.94
- RLAY $3.60
- Analyst Decision
- TECH Buy
- RLAY Strong Buy
- Analyst Count
- TECH 12
- RLAY 11
- Target Price
- TECH $70.00
- RLAY $18.40
- AVG Volume (30 Days)
- TECH 1.9M
- RLAY 1.5M
- Earning Date
- TECH 08-06-2025
- RLAY 08-05-2025
- Dividend Yield
- TECH 0.59%
- RLAY N/A
- EPS Growth
- TECH N/A
- RLAY N/A
- EPS
- TECH 0.83
- RLAY N/A
- Revenue
- TECH $1,208,770,000.00
- RLAY $7,679,000.00
- Revenue This Year
- TECH $7.07
- RLAY $17.59
- Revenue Next Year
- TECH $5.72
- RLAY N/A
- P/E Ratio
- TECH $65.29
- RLAY N/A
- Revenue Growth
- TECH 4.72
- RLAY N/A
- 52 Week Low
- TECH $46.01
- RLAY $1.78
- 52 Week High
- TECH $83.62
- RLAY $10.72
- Technical
- Relative Strength Index (RSI)
- TECH 59.94
- RLAY 57.25
- Support Level
- TECH $50.97
- RLAY $3.50
- Resistance Level
- TECH $55.53
- RLAY $3.86
- Average True Range (ATR)
- TECH 2.07
- RLAY 0.18
- MACD
- TECH 0.24
- RLAY 0.02
- Stochastic Oscillator
- TECH 77.60
- RLAY 65.79
About TECH Bio-Techne Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).